ERBB2 and breast carcinoma: Therefore, while the current results provide some insight into the regulatory factors controlling EDI3 expression, further investigations and experimental approaches are needed to conclusively elucidate how EDI3 is regulated in HER2 positive breast cancer, and the consequence of having high EDI3 expression in this specific subtype.